AAM names 2023 board of directorsChristine Baeder, senior vice president and chief operating officer for U.S. generics, Teva Pharmaceuticals USA is the 2023 AAM chair of the board. Alembic launches generic LatudaGeneric Latuda is used to treat a depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients as monotherapy. There are some tough-love lessons to be learned from the events of the past year An aging population combined with increasing numbers of people diagnosed with chronic diseases are among the top factors set to influence innovation in the generics drug market in 2023. Alembic launches desonide cream Alembic’s desonide cream 0.05% is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatosis. Alembic intros generic Taxol Paclitaxel injection solution is indicated for several different types of cancer. Sandoz biologics license application for denosumab accepted by FDA Denosumab is indicated for treating variety of conditions, such as osteoporosis in postmenopausal women. Teva to pay Florida $6.73M to settle state’s price fixing claims Teva will pay Florida $6.73 million, and the state will dismiss all of its claims against the company and its affiliates once payment has been made. Lupin receives tentative nod from FDA for DETAF DETAF would be used for the management of HIV infections and will be available for low- and middle-income countries. Aurobindo receives FDA nod for generic Pennsaid Diclofenac sodium topical solution is indicated for the treatment of osteoarthritis. Alvotech, Advanz Pharma enter commercialization agreement for Xolair biosimilar Omalizumab is used to treat patients with allergic asthma, chronic spontaneous urticaria and nasal polyps. First Previous 71 72 73 74 75 Next Last
